Haleon: If Staples Hold Up, The Stock Should Outperform (NYSE:HLN)

· seekingalpha.com

Haleon has underperformed since its 2022 spin from GSK, delivering just over 6% annualized returns, including dividends. Read why HLN stock is a Buy.

In its four-plus years as an independent company, Haleon ( HLN ) has underperformed. The consumer products giant, spun from GSK ( GSK ) in 2022, has returned a ...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI